Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. McCulloch on the Likelihood of Relapse on a BTK Inhibitor in MCL

September 4th 2019

Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the likelihood of relapse on a BTK inhibitor in mantle cell lymphoma (MCL).

Vorinostat Triplet Elicits High Responses in Newly Diagnosed MCL

August 30th 2019

The triplet regimen of vorinostat (Zolinza), cladribine, and rituximab (Rituxan) demonstrated an objective response rate of 97% and a complete response rate of 80% in newly diagnosed patients with mantle cell lymphoma.

FDA Grants Zanubrutinib Priority Review for Relapsed/Refractory Mantle Cell Lymphoma

August 22nd 2019

The FDA has granted a priority review designation to a new drug application for zanubrutinib for the treatment of patients with mantle cell lymphoma who have received ≥1 prior therapy.

Dr. Martin on Ibrutinib/Palbociclib Combo in Ibrutinib-Resistant MCL

August 16th 2019

Peter Martin, MD, discusses a phase I trial examining the ibrutinib plus palbociclib combination in ibrutinib-resistant patients with mantle cell lymphoma.

Expert Reflects on Rapidly Evolving Field of MCL

August 15th 2019

Simon Rule, MD, PhD, discusses the current treatment options in mantle cell lymphoma and explained how anticipated research results could be integrated into the field.

Dr. Rule on the Treatment Paradigm in MCL

August 14th 2019

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, discusses the treatment paradigm in mantle cell lymphoma (MCL).

Mantle Cell Lymphoma Options Expand, With CAR-T on the Horizon

August 8th 2019

Kieron Dunleavy, MD, discusses the current treatment paradigm in mantle call lymphoma and the emerging potential for CAR T-cell therapy.

Dr. Rule on Standard of Care in MCL

August 8th 2019

Simon Rule, MD, PhD, professor of haematology, Plymouth University Medical School, discusses the standard of care for mantle cell lymphoma in various patient subsets.

Frontline Mantle Cell Lymphoma Treatment Must Involve Personalized Approach

August 7th 2019

Peter Martin, MD, discusses the need for a personalized therapeutic approach in frontline MCL treatment.

Dr. Martin on Intensive Therapy for Young Patients with MCL

August 6th 2019

Peter Martin, MD, associate professor of medicine, chief, the Lymphoma Program, Meyer Cancer Center, Weill Cornell Medicine, discusses standard of care for younger patients with mantle cell lymphoma.

Dr. Rule on the Combination of Venetoclax and Ibrutinib in MCL

August 3rd 2019

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, discusses the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in mantle cell lymphoma (MCL).

Zanubrutinib Continues to Show Encouraging Activity in Relapsed/Refractory MCL

July 19th 2019

Yuqin Song, MD, PhD, discusses the clinical activity with zanubrutinib in patients with relapsed/refractory mantle cell lymphoma.

Rituximab Regimen Elicits High ORR in Relapsed MCL

July 17th 2019

Rory McCulloch, MD, discusses the results of a retrospective analysis looking at rituximab, bendamustine, and cytarabine in patients with mantle cell lymphoma who have relapsed on a BTK inhibitor.

Wang Explores Feasibility of CAR T Cells, Personalized Medicine in MCL

July 17th 2019

Michael Wang, MD, provides insight on recent advances in mantle cell lymphoma as well as research efforts for patients with a high risk of relapse.

Dr. Karmali on Next Steps of Research Regarding Ibrutinib Maintenance in MCL

July 12th 2019

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the next steps for research regarding the use of ibrutinib (Imbruvica) as maintenance therapy in mantle cell lymphoma (MCL).

Lisocabtagene Maraleucel Shows Promising Response Rates in Relapsed/Refractory MCL

July 11th 2019

The CAR T-cell therapy lisocabtagene maraleucel elicited a 71% overall response rate as well as a tolerable safety profile in a cohort of patients with relapsed/refractory mantle cell lymphoma.

Dr. McCulloch on the Use of R-BAC in MCL After Progression on BTK Therapy

July 11th 2019

Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the use of R-BAC (rituximab [Rituxan],bendamustine, and cytarabine) in patients with mantle cell lymphoma (MCL) who had progressed on initial therapy with a BTK inhibitor.

Dr. Karmali on Challenges in MCL

July 11th 2019

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses challenges in the field of mantle cell lymphoma (MCL).

Dr. Elhassadi on the Subtypes of MCL

July 10th 2019

Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses the subtypes of mantle cell lymphoma (MCL).

Dr. Karmali on the Toxicity Profile of Ibrutinib Maintenance in MCL

July 4th 2019

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the toxicity profile of ibrutinib (Imbruvica) maintenance therapy after induction therapy in patients with mantle cell lymphoma (MCL).